-
1
-
-
15544365329
-
Selective estrogen-receptor modulators for primary prevention of breast cancer
-
C.J. Fabian, B.F. Kimler, Selective estrogen-receptor modulators for primary prevention of breast cancer, J. Clin. Oncol. 23 (8) (2005) 1644-1655.
-
(2005)
J. Clin. Oncol.
, vol.23
, Issue.8
, pp. 1644-1655
-
-
Fabian, C.J.1
Kimler, B.F.2
-
2
-
-
18844443185
-
Aromatase inhibitors in the treatment of breast cancer
-
R.W. Brueggemeier, J.C. Hackett, E.S. Diaz-Cruz, Aromatase inhibitors in the treatment of breast cancer, Endocr. Rev. 26 (3) (2005) 331-345.
-
(2005)
Endocr. Rev.
, vol.26
, Issue.3
, pp. 331-345
-
-
Brueggemeier, R.W.1
Hackett, J.C.2
Diaz-Cruz, E.S.3
-
3
-
-
33846619697
-
Molecular basis for the aromatization reaction and exemestane-mediated irreversible inhibition of human aromatase
-
Y. Hong, B. Yu, M. Sherman, Y.C. Yuan, D. Zhou, S. Chen, Molecular basis for the aromatization reaction and exemestane-mediated irreversible inhibition of human aromatase, Mol. Endocrinol. 21 (2) (2007) 401-414.
-
(2007)
Mol. Endocrinol.
, vol.21
, Issue.2
, pp. 401-414
-
-
Hong, Y.1
Yu, B.2
Sherman, M.3
Yuan, Y.C.4
Zhou, D.5
Chen, S.6
-
4
-
-
33947510501
-
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98
-
A.S. Coates, A. Keshaviah, B. Thurlimann, H. Mouridsen, L. Mauriac, J.F. Forbes, R. Paridaens, M. Castiglione-Gertsch, R.D. Gelber, M. Colleoni, et al., Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98, J. Clin. Oncol. 25 (5) (2007) 486-492.
-
(2007)
J. Clin. Oncol.
, vol.25
, Issue.5
, pp. 486-492
-
-
Coates, A.S.1
Keshaviah, A.2
Thurlimann, B.3
Mouridsen, H.4
Mauriac, L.5
Forbes, J.F.6
Paridaens, R.7
Castiglione-Gertsch, M.8
Gelber, R.D.9
Colleoni, M.10
-
5
-
-
10744223655
-
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
-
DOI 10.1056/NEJMoa040331
-
R.C. Coombes, E. Hall, L.J. Gibson, R. Paridaens, J. Jassem, T. Delozier, S.E. Jones, I. Alvarez, G. Bertelli, O. Ortmann, et al., A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer, N. Engl. J. Med. 350 (11) (2004) 1081-1092. (Pubitemid 38298988)
-
(2004)
New England Journal of Medicine
, vol.350
, Issue.11
, pp. 1081-1092
-
-
Coombes, R.C.1
Hall, E.2
Gibson, L.J.3
Paridaens, R.4
Jassem, J.5
Delozier, T.6
Jones, S.E.7
Alvarez, I.8
Bertelli, G.9
Ortmann, O.10
Coates, A.S.11
Bajetta, E.12
Dodwell, D.13
Coleman, R.E.14
Fallowfield, L.J.15
Mickiewicz, E.16
Andersen, J.17
Lonning, P.E.18
Cocconi, G.19
Stewart, A.20
Stuart, N.21
Snowdon, C.F.22
Carpentieri, M.23
Massimini, G.24
Bliss, J.M.25
more..
-
6
-
-
7444259675
-
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer
-
P.E. Goss, J.N. Ingle, S. Martino, N.J. Robert, H.B. Muss, M.J. Piccart, M. Castiglione, D. Tu, L.E. Shepherd, K.I. Pritchard, et al., A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer, N. Engl. J. Med. 349 (19) (2003) 1793-1802.
-
(2003)
N. Engl. J. Med.
, vol.349
, Issue.19
, pp. 1793-1802
-
-
Goss, P.E.1
Ingle, J.N.2
Martino, S.3
Robert, N.J.4
Muss, H.B.5
Piccart, M.J.6
Castiglione, M.7
Tu, D.8
Shepherd, L.E.9
Pritchard, K.I.10
-
7
-
-
11444251764
-
Results of the ATAC (Arimidex, Tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer
-
A. Howell, J. Cuzick, M. Baum, A. Buzdar, M. Dowsett, J.F. Forbes, G. Hoctin-Boes, J. Houghton, G.Y. Locker, J.S. Tobias, Results of the ATAC (Arimidex, Tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer, Lancet 365 (9453) (2005) 60-62.
-
(2005)
Lancet
, vol.365
, Issue.9453
, pp. 60-62
-
-
Howell, A.1
Cuzick, J.2
Baum, M.3
Buzdar, A.4
Dowsett, M.5
Forbes, J.F.6
Hoctin-Boes, G.7
Houghton, J.8
Locker, G.Y.9
Tobias, J.S.10
-
8
-
-
49649111492
-
Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor
-
S. Masri, S. Phung, X. Wang, X. Wu, Y.C. Yuan, L. Wagman, S. Chen, Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor, Cancer Res. 68 (12) (2008) 4910-4918.
-
(2008)
Cancer Res.
, vol.68
, Issue.12
, pp. 4910-4918
-
-
Masri, S.1
Phung, S.2
Wang, X.3
Wu, X.4
Yuan, Y.C.5
Wagman, L.6
Chen, S.7
-
9
-
-
70349578803
-
Characterization of the weak estrogen receptor alpha agonistic activity of exemestane
-
S. Masri, K. Lui, S. Phung, J. Ye, D. Zhou, X. Wang, S. Chen, Characterization of the weak estrogen receptor alpha agonistic activity of exemestane, Breast Cancer Res. Treat. 116 (3) (2009) 461-470.
-
(2009)
Breast Cancer Res. Treat.
, vol.116
, Issue.3
, pp. 461-470
-
-
Masri, S.1
Lui, K.2
Phung, S.3
Ye, J.4
Zhou, D.5
Wang, X.6
Chen, S.7
-
10
-
-
42049120692
-
The role of amphiregulin in exemestaneresistant breast cancer cells: Evidence of an autocrine loop
-
X. Wang, S. Masri, S. Phung, S. Chen, The role of amphiregulin in exemestaneresistant breast cancer cells: evidence of an autocrine loop, Cancer Res. 68 (7) (2008) 2259-2265.
-
(2008)
Cancer Res.
, vol.68
, Issue.7
, pp. 2259-2265
-
-
Wang, X.1
Masri, S.2
Phung, S.3
Chen, S.4
-
11
-
-
0031458548
-
Autocrine and paracrine actions of breast tumor aromatase. A three-dimensional cell culture study involving aromatase transfected MCF-7 and T-47D cells
-
X.Z. Sun, D. Zhou, S. Chen, Autocrine and paracrine actions of breast tumor aromatase. A three-dimensional cell culture study involving aromatase transfected MCF-7 and T-47D cells, J. Steroid Biochem. Mol. Biol. 63 (1-3) (1997) 29-36.
-
(1997)
J. Steroid Biochem. Mol. Biol.
, vol.63
, Issue.1-3
, pp. 29-36
-
-
Sun, X.Z.1
Zhou, D.2
Chen, S.3
-
12
-
-
33751009646
-
What do we know about the mechanisms of aromatase inhibitor resistance?
-
S. Chen, S. Masri, X. Wang, S. Phung, Y.C. Yuan, X. Wu,What do we know about the mechanisms of aromatase inhibitor resistance? J. Steroid Biochem. Mol. Biol. 102 (1-5) (2006) 232-240.
-
(2006)
J. Steroid Biochem. Mol. Biol.
, vol.102
, Issue.1-5
, pp. 232-240
-
-
Chen, S.1
Masri, S.2
Wang, X.3
Phung, S.4
Yuan, Y.C.5
Wu, X.6
-
13
-
-
33751275796
-
Aromatase destabilizer: Novel action of exemestane, a food and drug administration-approved aromatase inhibitor
-
X. Wang, S. Chen, Aromatase destabilizer: novel action of exemestane, a food and drug administration-approved aromatase inhibitor, Cancer Res. 66 (21) (2006) 10281-10286.
-
(2006)
Cancer Res.
, vol.66
, Issue.21
, pp. 10281-10286
-
-
Wang, X.1
Chen, S.2
-
14
-
-
34247266976
-
Aromatase inhibitors and bone health in women with breast cancer
-
A.J. Chien, P.E. Goss, Aromatase inhibitors and bone health in women with breast cancer, J. Clin. Oncol. 24 (33) (2006) 5305-5312.
-
(2006)
J. Clin. Oncol.
, vol.24
, Issue.33
, pp. 5305-5312
-
-
Chien, A.J.1
Goss, P.E.2
-
15
-
-
33748776260
-
Bone safety of aromatase inhibitors versus tamoxifen
-
P.E. Lonning, Bone safety of aromatase inhibitors versus tamoxifen, Int. J. Gynecol. Cancer 16 (Suppl. 2) (2006) 518-520.
-
(2006)
Int. J. Gynecol. Cancer
, vol.16
, Issue.SUPPL. 2
, pp. 518-520
-
-
Lonning, P.E.1
-
16
-
-
38549180762
-
Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer
-
E.A. Perez, Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer, Ann. Oncol. 18 (Suppl. 8) (2007), viii26-35.
-
(2007)
Ann. Oncol.
, vol.18
, Issue.SUPPL. 8
-
-
Perez, E.A.1
-
17
-
-
33846545488
-
Skeletal effects of exemestane on bonemineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): A randomised controlled study
-
R.E. Coleman, L.M. Banks, S.I. Girgis, L.S. Kilburn, E. Vrdoljak, J. Fox, S.J. Cawthorn, A. Patel, C.F. Snowdon, E. Hall, et al., Skeletal effects of exemestane on bonemineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study, Lancet Oncol. 8 (2) (2007) 119-127.
-
(2007)
Lancet Oncol.
, vol.8
, Issue.2
, pp. 119-127
-
-
Coleman, R.E.1
Banks, L.M.2
Girgis, S.I.3
Kilburn, L.S.4
Vrdoljak, E.5
Fox, J.6
Cawthorn, S.J.7
Patel, A.8
Snowdon, C.F.9
Hall, E.10
-
18
-
-
36549088561
-
Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women
-
P.E. Goss, P. Hadji, M. Subar, P. Abreu, T. Thomsen, J. Banke-Bochita, Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women, Breast Cancer Res. 9 (4) (2007) R52.
-
(2007)
Breast Cancer Res.
, vol.9
, Issue.4
-
-
Goss, P.E.1
Hadji, P.2
Subar, M.3
Abreu, P.4
Thomsen, T.5
Banke-Bochita, J.6
-
19
-
-
1242338758
-
Selective estrogen receptor modulators: Discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells
-
J. Frasor, F. Stossi, J.M. Danes, B. Komm, C.R. Lyttle, B.S. Katzenellenbogen, Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells, Cancer Res. 64 (4) (2004) 1522-1533.
-
(2004)
Cancer Res.
, vol.64
, Issue.4
, pp. 1522-1533
-
-
Frasor, J.1
Stossi, F.2
Danes, J.M.3
Komm, B.4
Lyttle, C.R.5
Katzenellenbogen, B.S.6
-
20
-
-
0029092283
-
Estrogen and phorbol esters regulate amphiregulin expression by two separate mechanisms in human breast cancer cell lines
-
I. Martinez-Lacaci, M. Saceda, G.D. Plowman, G.R. Johnson, N. Normanno, D.S. Salomon, R.B. Dickson, Estrogen and phorbol esters regulate amphiregulin expression by two separate mechanisms in human breast cancer cell lines, Endocrinology 136 (9) (1995) 3983-3992.
-
(1995)
Endocrinology
, vol.136
, Issue.9
, pp. 3983-3992
-
-
Martinez-Lacaci, I.1
Saceda, M.2
Plowman, G.D.3
Johnson, G.R.4
Normanno, N.5
Salomon, D.S.6
Dickson, R.B.7
-
21
-
-
34447330435
-
Amphiregulin: A new growth factor in hepatocarcinogenesis
-
C. Berasain, J. Castillo, M.J. Perugorria, J. Prieto, M.A. Avila, Amphiregulin: a new growth factor in hepatocarcinogenesis, Cancer Lett. 254 (1) (2007) 30-41.
-
(2007)
Cancer Lett.
, vol.254
, Issue.1
, pp. 30-41
-
-
Berasain, C.1
Castillo, J.2
Perugorria, M.J.3
Prieto, J.4
Avila, M.A.5
-
22
-
-
0024593476
-
Structure and function ofhumanamphiregulin: Amember of the epidermal growth factor family
-
M. Shoyab, G.D. Plowman, V.L. McDonald, J.G. Bradley, G.J. Todaro, Structure and function ofhumanamphiregulin: amember of the epidermal growth factor family, Science 243 (4894 Pt 1) (1989) 1074-1076.
-
(1989)
Science
, vol.243
, Issue.4894 PART 1
, pp. 1074-1076
-
-
Shoyab, M.1
Plowman, G.D.2
McDonald, V.L.3
Bradley, J.G.4
Todaro, G.J.5
-
23
-
-
49649112223
-
Stopping treatment can reverse acquired resistance to letrozole
-
G.J. Sabnis, L.F. Macedo, O. Goloubeva, A. Schayowitz, A.M. Brodie, Stopping treatment can reverse acquired resistance to letrozole, Cancer Res. 68 (12) (2008) 4518-4524.
-
(2008)
Cancer Res.
, vol.68
, Issue.12
, pp. 4518-4524
-
-
Sabnis, G.J.1
MacEdo, L.F.2
Goloubeva, O.3
Schayowitz, A.4
Brodie, A.M.5
-
24
-
-
0027416692
-
Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen
-
K. Akakura, N. Bruchovsky, S.L. Goldenberg, P.S. Rennie, A.R. Buckley, L.D. Sullivan, Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen, Cancer 71 (9) (1993) 2782-2790.
-
(1993)
Cancer
, vol.71
, Issue.9
, pp. 2782-2790
-
-
Akakura, K.1
Bruchovsky, N.2
Goldenberg, S.L.3
Rennie, P.S.4
Buckley, A.R.5
Sullivan, L.D.6
-
25
-
-
0027287757
-
Autocrine regulation of prostate-specific antigen gene expression in a human prostatic cancer (LNCaP) subline
-
J.T. Hsieh, H.C. Wu, M.E. Gleave, A.C. von Eschenbach, L.W. Chung, Autocrine regulation of prostate-specific antigen gene expression in a human prostatic cancer (LNCaP) subline, Cancer Res. 53 (12) (1993) 2852-2857.
-
(1993)
Cancer Res.
, vol.53
, Issue.12
, pp. 2852-2857
-
-
Hsieh, J.T.1
Wu, H.C.2
Gleave, M.E.3
Von Eschenbach, A.C.4
Chung, L.W.5
-
26
-
-
57649174634
-
MicroRNA-221/222 negatively regulates estrogen receptor{alpha} and is associated with tamoxifen resistance in breast cancer
-
J.J. Zhao, J. Lin, H. Yang, W. Kong, L. He, X. Ma, D. Coppola, J.Q. Cheng, MicroRNA-221/222 negatively regulates estrogen receptor{alpha} and is associated with tamoxifen resistance in breast cancer, J. Biol. Chem. 283 (45) (2008) 31079-31086.
-
(2008)
J. Biol. Chem.
, vol.283
, Issue.45
, pp. 31079-31086
-
-
Zhao, J.J.1
Lin, J.2
Yang, H.3
Kong, W.4
He, L.5
Ma, X.6
Coppola, D.7
Cheng, J.Q.8
-
27
-
-
56449092072
-
MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1
-
T.E. Miller, K. Ghoshal, B. Ramaswamy, S. Roy, J. Datta, C.L. Shapiro, S. Jacob, S. Majumder, MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1, J. Biol. Chem. 283 (44) (2008) 29897-29903.
-
(2008)
J. Biol. Chem.
, vol.283
, Issue.44
, pp. 29897-29903
-
-
Miller, T.E.1
Ghoshal, K.2
Ramaswamy, B.3
Roy, S.4
Datta, J.5
Shapiro, C.L.6
Jacob, S.7
Majumder, S.8
-
28
-
-
51049104524
-
Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin
-
O. Kovalchuk, J. Filkowski, J. Meservy, Y. Ilnytskyy, V.P. Tryndyak, V.F. Chekhun, I.P. Pogribny, Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin, Mol. Cancer Ther. 7 (7) (2008) 2152-2159.
-
(2008)
Mol. Cancer Ther.
, vol.7
, Issue.7
, pp. 2152-2159
-
-
Kovalchuk, O.1
Filkowski, J.2
Meservy, J.3
Ilnytskyy, Y.4
Tryndyak, V.P.5
Chekhun, V.F.6
Pogribny, I.P.7
-
29
-
-
48249098902
-
Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM
-
L. Fontana, M.E. Fiori, S. Albini, L. Cifaldi, S. Giovinazzi, M. Forloni, R. Boldrini, A. Donfrancesco, V. Federici, P. Giacomini, et al., Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM, PLoS ONE 3 (5) (2008) e2236.
-
(2008)
PLoS ONE
, vol.3
, Issue.5
-
-
Fontana, L.1
Fiori, M.E.2
Albini, S.3
Cifaldi, L.4
Giovinazzi, S.5
Forloni, M.6
Boldrini, R.7
Donfrancesco, A.8
Federici, V.9
Giacomini, P.10
-
30
-
-
44949249814
-
MiR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells
-
L. Xia, D. Zhang, R. Du, Y. Pan, L. Zhao, S. Sun, L. Hong, J. Liu, D. Fan, miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells, Int. J. Cancer 123 (2) (2008) 372-379.
-
(2008)
Int. J. Cancer
, vol.123
, Issue.2
, pp. 372-379
-
-
Xia, L.1
Zhang, D.2
Du, R.3
Pan, Y.4
Zhao, L.5
Sun, S.6
Hong, L.7
Liu, J.8
Fan, D.9
-
31
-
-
42749093490
-
MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer
-
M. Garofalo, C. Quintavalle, G. Di Leva, C. Zanca, G. Romano, C. Taccioli, C.G. Liu, C.M. Croce, G. Condorelli, MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer, Oncogene 27 (27) (2008) 3845-3855.
-
(2008)
Oncogene
, vol.27
, Issue.27
, pp. 3845-3855
-
-
Garofalo, M.1
Quintavalle, C.2
Di Leva, G.3
Zanca, C.4
Romano, G.5
Taccioli, C.6
Liu, C.G.7
Croce, C.M.8
Condorelli, G.9
-
32
-
-
39049086391
-
MicroRNA expression profiling in human ovarian cancer: MiR-214 induces cell survival and cisplatin resistance by targeting PTEN
-
H. Yang, W. Kong, L. He, J.J. Zhao, J.D. O'Donnell, J. Wang, R.M. Wenham, D. Coppola, P.A. Kruk, S.V. Nicosia, et al., MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN, Cancer Res. 68 (2) (2008) 425-433.
-
(2008)
Cancer Res.
, vol.68
, Issue.2
, pp. 425-433
-
-
Yang, H.1
Kong, W.2
He, L.3
Zhao, J.J.4
O'Donnell, J.D.5
Wang, J.6
Wenham, R.M.7
Coppola, D.8
Kruk, P.A.9
Nicosia, S.V.10
|